医学
基础(医学)
胰岛素
基础胰岛素
内科学
内分泌学
糖尿病
2型糖尿病
生物信息学
梅德林
作者
Theocharis Koufakis,Dimitrios Patoulias,Djordje S. Popovic,Vasilis Tsimihodimos
标识
DOI:10.1080/17446651.2025.2580629
摘要
INTRODUCTION: Basal insulin has long served as a cornerstone in the management of type 2 diabetes. However, the emergence of glucose-lowering agents with cardiometabolic benefits - such as glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and dual incretin receptor agonists - has prompted a reassessment of insulin's role in the modern therapeutic landscape. AREAS COVERED: This article reviews recent evidence from cardiovascular outcomes trials and head-to-head studies comparing newer agents to basal insulin. A targeted literature search was conducted using PubMed and major diabetes guidelines to identify high-quality studies and recommendations. The discussion covers clinical scenarios where basal insulin remains essential, the benefits of combination therapy, and the impact of recent innovations such as once-weekly insulin formulations. EXPERT OPINION: While modern therapies are increasingly prioritized due to superior efficacy, safety, and weight benefits, basal insulin remains indispensable for patients with advanced β-cell failure, symptomatic hyperglycemia, or contraindications to newer agents. Personalized, pathophysiology-driven strategies should guide therapy selection, including the integration of basal insulin where appropriate.
科研通智能强力驱动
Strongly Powered by AbleSci AI